{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:35:08Z","timestamp":1780050908673,"version":"3.53.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:00:00Z","timestamp":1604102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:00:00Z","timestamp":1604102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00345-020-03502-7","type":"journal-article","created":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T07:03:01Z","timestamp":1604127781000},"page":"1357-1367","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Immune checkpoint inhibition in upper tract urothelial carcinoma"],"prefix":"10.1007","volume":"39","author":[{"given":"Gianluigi","family":"Califano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idir","family":"Ouzaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Verze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Francois","family":"Hermieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Mirone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9440-4895","authenticated-orcid":false,"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,31]]},"reference":[{"key":"3502_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7\u201330. https:\/\/doi.org\/10.3322\/caac.21590","journal-title":"CA Cancer J Clin"},{"key":"3502_CR2","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359-386. https:\/\/doi.org\/10.1002\/ijc.29210","journal-title":"Int J Cancer"},{"key":"3502_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.eururo.2017.07.036","volume":"73","author":"M Roupr\u00eat","year":"2018","unstructured":"Roupr\u00eat M, Babjuk M, Comp\u00e9rat E, Zigeuner R, Sylvester RJ, Burger M et al (2018) European association of urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. Eur Urol 73:111\u2013122. https:\/\/doi.org\/10.1016\/j.eururo.2017.07.036","journal-title":"Eur Urol"},{"key":"3502_CR4","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","volume":"395","author":"A Birtle","year":"2020","unstructured":"Birtle A, Johnson M, Chester J, Jones R, Dolling D, Bryan RT et al (2020) Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet 395:1268\u20131277. https:\/\/doi.org\/10.1016\/S0140-6736(20)30415-3","journal-title":"Lancet"},{"key":"3502_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000644","author":"V Margulis","year":"2019","unstructured":"Margulis V, Puligandla M, Trabulsi EJ, Plimack ER, Kessler ER, Matin SF et al (2019) Phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high grade upper tract urothelial carcinoma. J Urol. https:\/\/doi.org\/10.1097\/JU.0000000000000644","journal-title":"J Urol"},{"key":"3502_CR6","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","volume":"10","author":"PJ Loehrer","year":"1992","unstructured":"Loehrer PJ, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I et al (1992) A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10:1066\u20131073. https:\/\/doi.org\/10.1200\/JCO.1992.10.7.1066","journal-title":"J Clin Oncol"},{"key":"3502_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.03.055","author":"JA Witjes","year":"2020","unstructured":"Witjes JA, Bruins HM, Cathomas R, Comp\u00e9rat EM, Cowan NC, Gakis G et al (2020) European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2020.03.055","journal-title":"Eur Urol"},{"key":"3502_CR8","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.eururo.2020.04.008","volume":"78","author":"G Califano","year":"2020","unstructured":"Califano G, Xylinas E (2020) Re: phase II trial of neoadjuvant systemic chemotherapy followed by extirpative surgery in patients with high grade upper tract urothelial carcinoma. Eur Urol 78:113\u2013114. https:\/\/doi.org\/10.1016\/j.eururo.2020.04.008","journal-title":"Eur Urol"},{"key":"3502_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I (2013) Oncology meets immunology: the cancer-immunity cycle. Immunity 39:1\u201310. https:\/\/doi.org\/10.1016\/j.immuni.2013.07.012","journal-title":"Immunity"},{"key":"3502_CR10","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3:991\u2013998. https:\/\/doi.org\/10.1038\/ni1102-991","journal-title":"Nat Immunol"},{"key":"3502_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ctrv.2017.01.007","volume":"54","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, Powles T, Vogelzang NJ (2017) A review on the evolution of PD-1\/PD-L1 immunotherapy for bladder cancer: the future is now. Cancer Treat Rev 54:58\u201367. https:\/\/doi.org\/10.1016\/j.ctrv.2017.01.007","journal-title":"Cancer Treat Rev"},{"key":"3502_CR12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","volume":"81","author":"LA Emens","year":"2017","unstructured":"Emens LA, Ascierto PA, Darcy PK, Demaria S, Eggermont AMM, Redmond WL et al (2017) Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape. Eur J Cancer 81:116\u2013129. https:\/\/doi.org\/10.1016\/j.ejca.2017.01.035","journal-title":"Eur J Cancer"},{"key":"3502_CR13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S1470-2045(10)70275-8","volume":"12","author":"MD Galsky","year":"2011","unstructured":"Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK et al (2011a) A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol 12:211\u2013214. https:\/\/doi.org\/10.1016\/S1470-2045(10)70275-8","journal-title":"Lancet Oncol"},{"key":"3502_CR14","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","volume":"29","author":"MD Galsky","year":"2011","unstructured":"Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK et al (2011b) Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for Cisplatin-based chemotherapy. J Clin Oncol 29:2432\u20132438. https:\/\/doi.org\/10.1200\/JCO.2011.34.8433","journal-title":"J Clin Oncol"},{"key":"3502_CR15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","volume":"30","author":"M De Santis","year":"2012","unstructured":"De Santis M, Bellmunt J, Mead G, Kerst JM, Leahy M, Maroto P et al (2012) Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 30:191\u2013199. https:\/\/doi.org\/10.1200\/JCO.2011.37.3571","journal-title":"J Clin Oncol"},{"key":"3502_CR16","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1093\/annonc\/mdv609","volume":"27","author":"M De Santis","year":"2016","unstructured":"De Santis M, Wiechno PJ, Bellmunt J, Lucas C, Su W-C, Albiges L et al (2016) Vinflunine-gemcitabine versus vinflunine-carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomized phase II trial (JASINT1). Ann Oncol 27:449\u2013454. https:\/\/doi.org\/10.1093\/annonc\/mdv609","journal-title":"Ann Oncol"},{"issue":"23\u201330","key":"3502_CR17","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1016\/j.clgc.2016.05.003","volume":"15","author":"A Necchi","year":"2017","unstructured":"Necchi A, Pond GR, Raggi D, Giannatempo P, Vogelzang NJ, Grivas P et al (2017) Efficacy and safety of gemcitabine plus either taxane or carboplatin in the first-line setting of metastatic urothelial carcinoma: a systematic review and meta-analysis. Clin Genitourin Cancer 15(23\u201330):e2. https:\/\/doi.org\/10.1016\/j.clgc.2016.05.003","journal-title":"Clin Genitourin Cancer"},{"key":"3502_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar AV, Galsky MD, Rosenberg JE, Powles T, Petrylak DP, Bellmunt J et al (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. Lancet 389:67\u201376. https:\/\/doi.org\/10.1016\/S0140-6736(16)32455-2","journal-title":"Lancet"},{"key":"3502_CR19","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","volume":"18","author":"AV Balar","year":"2017","unstructured":"Balar AV, Castellano D, O\u2019Donnell PH, Grivas P, Vuky J, Powles T et al (2017) First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol 18:1483\u20131492. https:\/\/doi.org\/10.1016\/S1470-2045(17)30616-2","journal-title":"Lancet Oncol"},{"key":"3502_CR20","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","volume":"395","author":"MD Galsky","year":"2020","unstructured":"Galsky MD, Arija J\u00c1A, Bamias A, Davis ID, De Santis M, Kikuchi E et al (2020) Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 395:1547\u20131557. https:\/\/doi.org\/10.1016\/S0140-6736(20)30230-0","journal-title":"Lancet"},{"key":"3502_CR21","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1200\/JCO.2011.38.6979","volume":"30","author":"J Bellmunt","year":"2012","unstructured":"Bellmunt J, von der Maase H, Mead GM, Skoneczna I, De Santis M, Daugaard G et al (2012) Randomized phase III study comparing paclitaxel\/cisplatin\/gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 30:1107\u20131113. https:\/\/doi.org\/10.1200\/JCO.2011.38.6979","journal-title":"J Clin Oncol"},{"key":"3502_CR22","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:1909\u20131920. https:\/\/doi.org\/10.1016\/S0140-6736(16)00561-4","journal-title":"Lancet"},{"key":"3502_CR23","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee J-L, Fong L et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376:1015\u20131026. https:\/\/doi.org\/10.1056\/NEJMoa1613683","journal-title":"N Engl J Med"},{"key":"3502_CR24","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","volume":"391","author":"T Powles","year":"2018","unstructured":"Powles T, Dur\u00e1n I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U et al (2018) Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391:748\u2013757. https:\/\/doi.org\/10.1016\/S0140-6736(17)33297-X","journal-title":"Lancet"},{"key":"3502_CR25","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.eururo.2019.03.015","volume":"76","author":"CN Sternberg","year":"2019","unstructured":"Sternberg CN, Loriot Y, James N, Choy E, Castellano D, Lopez-Rios F et al (2019) Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of the urinary tract. Eur Urol 76:73\u201381. https:\/\/doi.org\/10.1016\/j.eururo.2019.03.015","journal-title":"Eur Urol"},{"key":"3502_CR26","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","volume":"19","author":"MR Patel","year":"2018","unstructured":"Patel MR, Ellerton J, Infante JR, Agrawal M, Gordon M, Aljumaily R et al (2018) Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol 19:51\u201364. https:\/\/doi.org\/10.1016\/S1470-2045(17)30900-2","journal-title":"Lancet Oncol"},{"key":"3502_CR27","doi-asserted-by":"publisher","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","volume":"3","author":"T Powles","year":"2017","unstructured":"Powles T, O\u2019Donnell PH, Massard C, Arkenau H-T, Friedlander TW, Hoimes CJ et al (2017) Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 open-label study. JAMA Oncol 3:e172411. https:\/\/doi.org\/10.1001\/jamaoncol.2017.2411","journal-title":"JAMA Oncol"},{"key":"3502_CR28","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","volume":"17","author":"P Sharma","year":"2016","unstructured":"Sharma P, Callahan MK, Bono P, Kim J, Spiliopoulou P, Calvo E et al (2016) Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial. Lancet Oncol 17:1590\u20131598. https:\/\/doi.org\/10.1016\/S1470-2045(16)30496-X","journal-title":"Lancet Oncol"},{"key":"3502_CR29","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J et al (2017) Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 18:312\u2013322. https:\/\/doi.org\/10.1016\/S1470-2045(17)30065-7","journal-title":"Lancet Oncol"},{"key":"3502_CR30","doi-asserted-by":"publisher","first-page":"4104","DOI":"10.1002\/cncr.24466","volume":"115","author":"G Sonpavde","year":"2009","unstructured":"Sonpavde G, Goldman BH, Speights VO, Lerner SP, Wood DP, Vogelzang NJ et al (2009) Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 115:4104\u20134109. https:\/\/doi.org\/10.1002\/cncr.24466","journal-title":"Cancer"},{"key":"3502_CR31","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1002\/cncr.29387","volume":"121","author":"MD Galsky","year":"2015","unstructured":"Galsky MD, Pal SK, Chowdhury S, Harshman LC, Crabb SJ, Wong Y-N et al (2015) Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer 121:2586\u20132593. https:\/\/doi.org\/10.1002\/cncr.29387","journal-title":"Cancer"},{"key":"3502_CR32","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.eururo.2014.09.007","volume":"67","author":"H Zargar","year":"2015","unstructured":"Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC et al (2015) Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol 67:241\u2013249. https:\/\/doi.org\/10.1016\/j.eururo.2014.09.007","journal-title":"Eur Urol"},{"key":"3502_CR33","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1200\/JCO.18.01148","volume":"36","author":"A Necchi","year":"2018","unstructured":"Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Lucian\u00f2 R et al (2018) Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm. Phase II Study J Clin Oncol 36:3353\u20133360. https:\/\/doi.org\/10.1200\/JCO.18.01148","journal-title":"Phase II Study J Clin Oncol"},{"key":"3502_CR34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.eururo.2019.02.027","volume":"76","author":"R Li","year":"2019","unstructured":"Li R, Spiess PE, Gilbert SM, Necchi A (2019) Towards personalized neoadjuvant therapy for muscle-invasive bladder cancer. Eur Urol 76:4\u20136. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.027","journal-title":"Eur Urol"},{"key":"3502_CR35","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.eururo.2019.05.041","volume":"76","author":"M-O Grimm","year":"2019","unstructured":"Grimm M-O, Bex A, De Santis M, Ljungberg B, Catto JWF, Roupr\u00eat M et al (2019) Safe use of immune checkpoint inhibitors in the multidisciplinary management of urological cancer: the European association of urology position in 2019. Eur Urol 76:368\u2013380. https:\/\/doi.org\/10.1016\/j.eururo.2019.05.041","journal-title":"Eur Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-020-03502-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-020-03502-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-020-03502-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,31]],"date-time":"2021-05-31T14:07:55Z","timestamp":1622470075000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-020-03502-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,31]]},"references-count":35,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["3502"],"URL":"https:\/\/doi.org\/10.1007\/s00345-020-03502-7","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,31]]},"assertion":[{"value":"20 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}